Galapagos lands $150M bounty in $1.35bn autoimmune deal with Abbott
This article was originally published in Scrip
Executive Summary
Galapagos, the profitable mid-sized European biotech, has signed up Abbott Laboratories as its partner to develop and commercialise an oral, next-generation Janus kinase (JAK) 1 inhibitor in multiple autoimmune diseases, including rheumatoid arthritis.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.